A/s Apothekernes Laboratorium for Specialpraeparater v. I.M.C. Chemical Group, Inc. And Dr. M.B. Gillis

873 F.2d 155, 1989 U.S. App. LEXIS 5862, 1989 WL 42627
CourtCourt of Appeals for the Seventh Circuit
DecidedApril 18, 1989
Docket88-1326
StatusPublished
Cited by56 cases

This text of 873 F.2d 155 (A/s Apothekernes Laboratorium for Specialpraeparater v. I.M.C. Chemical Group, Inc. And Dr. M.B. Gillis) is published on Counsel Stack Legal Research, covering Court of Appeals for the Seventh Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
A/s Apothekernes Laboratorium for Specialpraeparater v. I.M.C. Chemical Group, Inc. And Dr. M.B. Gillis, 873 F.2d 155, 1989 U.S. App. LEXIS 5862, 1989 WL 42627 (7th Cir. 1989).

Opinion

COFFEY, Circuit Judge.

This is a diversity case arising from Apothekernes’ unsuccessful attempt to purchase the Biochemical Division of IMC. The parties negotiated for some months in an attempt to reach an agreement on the terms of the sale. In February of 1978, the two companies’ negotiators were finally able to agree on all terms. However, IMC’s board of directors refused to approve the deal. Apothekernes filed this action asserting state law claims of breach of contract, fraud and estoppel. Following a bench trial, the district court, 678 F.Supp. 193 (N.D.I11.1988) entered judgment in favor of IMC on all counts. We affirm.

I

Apothekernes brought this suit against IMC on the theories of breach of contract, fraud and estoppel, seeking damages and specific performance of what it perceived as a consummated deal for the sale of IMC’s Biochemical Division. The district court initially granted summary judgment for IMC on the breach of contract and estoppel claims (leaving only the charges of fraudulent misrepresentation) and certified the dismissal of those counts for immediate appeal under Federal Rule of Civil Procedure 54(b). We dismissed that appeal for lack of jurisdiction holding that the claims certified for appeal were not “separate in a Rule 54(b) sense” from the claims the district court had retained. A/S Apotkekernes Laboratorium for Specialpraeparater v. I.M.C. Chemical Group, Inc., 725 F.2d 1140, 1143 (7th Cir.1984).

The case then proceeded to a bench trial and the district court made the following findings of fact and conclusions of law. In March of 1977, Apothekernes, through its *156 president, E.W. Sissener, began negotiating with IMC and its president and chief executive officer, Dr. M.B. Gillis, for the purchase of various of IMC’s assets. During the month of December in 1977, the scope of the deal had narrowed to the point that the parties were talking about the purchase of certain, though not all, of IMC’s Terre Haute plant facilities. On the 9th of December 1977, the parties signed a letter “intended to set forth the terms upon which we and/or our nominee intend to negotiate and consummate an Agreement of Sale relative to the purchase of certain assets of the Biochemical Division of IMC_” The letter set forth and delineated those matters upon which Sissener and Gillis had previously reached substantial agreement, as well as those issues that required further negotiation. The letter then concluded that “[a]ll of the above is subject to our concluding an Agreement of Sale which shall be acceptable to the Boards of Directors of our respective corporations, whose discretion shall in no way be limited by this letter ... In the interim, [IMC] agree[s] not to initiate negotiations or discussions intended to lead to negotiations with others for the sale of these same assets.” Finally, the letter provided for an Agreement of Sale to be executed within 60 days of December 9, 1977.

Initially, the court found that the December 9, 1977 letter of intent did not constitute a binding contract for the sale of IMC’s assets, but that it did serve to obligate both parties to bargain in good faith with the goal of eventually reaching agreement. According to the district court, although negotiations proceeded in good faith, by February 23, 1978 the parties still had not resolved their differences on three matters that the court considered “deal breakers.” The court concluded that because the sixty day period in which the parties had agreed to execute a final agreement had expired, Gillis was no longer obligated to continue negotiations and could have broken them off at any time. Nonetheless, Sissener capitulated on the three points of contention on February 24, and the court found that at that time, the parties had reached a “meeting of the minds on all substantial terms.” The court specifically found that up to this point, Gillis had negotiated in good faith and had reached agreement with Sissener.

According to the district court, the February 24 meeting of the minds did not, however, constitute a binding contract of sale. Though it determined that the lack of a final executed written draft did not preclude finding an intent to contract on February 24, it did find that the board approval provision in the December 9 letter of intent prevented the formalization of a binding contract absent the approval of IMC’s board of directors. The court also found that though Gillis “had perhaps indicated to Sissener his confidence that board approval would be forthcoming, there was no certainty that it would be granted.” Instead, the district court found that the board approval provision was explicit in the letter of intent; Gillis had neither the authority nor the apparent authority to bind IMC to the sale of substantial corporate assets, especially when the deal would have involved joint use of a production facility. Nor was the board bound by the letter of intent to accept the terms of the February 24 deal, even though it was reasonably in accord with the terms in the letter of intent; the letter of intent explicitly reserved to the board unlimited discretion to either accept or reject the deal.

Before taking the agreement to the IMC board of directors for approval, Gillis initially went to discuss the matter with Le-non, the president of IMC’s parent, as he told Sissener he would do. The court found that at the Gillis-Lenon meeting, Gil-lis did not take it upon himself to advocate the agreement, but rather focused on the protracted nature of the negotiations leading up to the agreement. Lenon in turn summarily rejected the deal. Lenon’s decision was, according to the district court, binding on Gillis and IMC’s board of directors. Accordingly, Gillis convened a telephone meeting of the board and induced them to reject the sale. The court concluded that the fact that the board’s decision was not an independent one, but instead was a rubber-stamp for Lenon’s decision, *157 was in no way improper. It found that Lenon could reject the sale to the same extent that the IMC board could reject the sale. Having determined that the letter of intent reserved to the board of directors the right to reject the deal, the court concluded that, “[bjefore there was a contract the IMC hoard had to approve what its negotiator had approved, and the IMC board would not approve unless Lenon approved, and Lenon said no. There was no contract.” Accordingly, the district court entered judgment in favor of IMC on all counts, which judgment Apothekemes now appeals.

II

Apothekemes presents two arguments on appeal. First, it argues that the February 24 meeting of the minds constituted a binding contract which IMC breached by refusing to go through with the proposed sale. Alternatively, Apothekemes argues that the December 9 letter of intent imposed a duty upon IMC to negotiate in good faith, which IMC breached when its board of directors rejected the proposal. We address each of these arguments.

A. The February 24 Meeting of the Minds

The district court found that on February 24, following Sissener’s capitulation on the three deal-breaking points, Sissener and Gillis had reached a meeting of the minds on all substantial points.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Dobson v. Ford Motor Company
N.D. Illinois, 2023
United States v. David Weimert
819 F.3d 351 (Seventh Circuit, 2016)
Typenex Co-Investment, LLC v. Solar Wind Energy Tower, Inc.
123 F. Supp. 3d 1017 (N.D. Illinois, 2015)
Butler v. Balolia
736 F.3d 609 (First Circuit, 2013)
Abdelrhman v. Ackerman
76 A.3d 883 (District of Columbia Court of Appeals, 2013)
Sea Hawk Seafoods, Inc. v. City of Valdez
282 P.3d 359 (Alaska Supreme Court, 2012)
Trovare Capital Group, LLC v. Simkins Industries, Inc.
646 F.3d 994 (Seventh Circuit, 2011)
Rambus Inc. v. Hynix Semiconductor Inc.
629 F. Supp. 2d 979 (N.D. California, 2009)
Weigel Broadcasting Co. v. Tv-49, Inc.
466 F. Supp. 2d 1011 (N.D. Illinois, 2006)
Norkunas v. Cochran
895 A.2d 1101 (Court of Special Appeals of Maryland, 2006)
SuperValu Inc. v. Associated Grocers, Inc.
428 F. Supp. 2d 985 (D. Minnesota, 2006)
JamSports and Entertainment, LLC v. PARADAMA PRODUCTION, INC.
336 F. Supp. 2d 824 (N.D. Illinois, 2004)

Cite This Page — Counsel Stack

Bluebook (online)
873 F.2d 155, 1989 U.S. App. LEXIS 5862, 1989 WL 42627, Counsel Stack Legal Research, https://law.counselstack.com/opinion/as-apothekernes-laboratorium-for-specialpraeparater-v-imc-chemical-ca7-1989.